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1026-l 04 The Effect of Vardenafil, a Selective PDE5 Inhibitor, on 
lschemic Threshold, Exercise Tolerance, and 
Circulatory Responses During Treadmill Exercise in 
Men With Stable Angina Pectoris 
UdhoThadani. Steven Chrysant, Arthur Mazzu. The Vardenafil Study Group, Oklahoma 
University Health Science Center, Oklahoma City, OK, Bayer Corporation, West Haven, 
CT 
Background: Erectile dysfunction (ED) IS common among men with CAD. Vardenafil (5, 
10, and 20mg) is an efficacious oral treatment for ED. The effects of vardenafil 1Omg on 
exercise parameters in patients with stable angina and reproducible exeltional cardiac 
ischemia were previously evaluated; this study examined the effects of vardenafil 20mg 
in a similar patient population. 
Methods: In this double-blind, crossover, single-dose, multicenter study, 39 men ran- 
domized to vardenafil 20mg or placebo were evaluated by symptom-limited exercise 
treadmill test (ETT) one hour post-dose, the time of maximal drug exposure. Nitrates 
were prohibited during the study. 
Results: Majority of men (mean age 63.6 y [range 48-80 y]) received beta-blockers (291 
39), aspirin (35/39) and lipid lowering drugs (29/39). Data derived during exercise is 
shown. 
Vardenafil 20 Placebo 
mg 
Parameter 
Treadmill Exercise Time’, set 
” Value n Value 
36 4142114 36 411+12 
4 
Time to Angina Pectoris’, first awareness, set 36 3542137 36 347+14 
3 
Time to ST-Segment depression> 1 mm a from 33 3642101 36 366+_10 
EL’. set 5 
Rate-pressure product, peak exercise*, mmHg x 39# 19.2k5.2 38 19.3+4. 
BPM x 10s’ # 3 
*-mean +sD, p>O.O5, based on LS geometric mean ratio of vardenafillplacebo. #- 
includes 3/2 patients in vardenafillplacebo groups respectively,excluded from ETT 
analysis because of protocol violations. 
Vardenafil was well tolerated. The most common adverse events during vardenafll treat- 
ment (facial flushing and headache) were mild or moderate and transient. One patient 
receiving vardenafil exhibited post-exercise transient hypotension and dizziness which 
resolved following oral fluid replacement. 
Conclusion: Vardenafil 20mg did not impair stable CAD patients’ ability to exercise or 
alter ischemic threshold at effort levels considered equal to or greater than sexual inter- 
course. 
1026-l 05 An Examination of Atorvastatin Safety When Used in 
Combination With Verapamil: Evidence From 44 
Completed Clinical Trials 
William J. Sasiela, Michael Szarek, Halit Silbershatz, Gary Palmer, Pfizer Inc., New York, 
NY 
Background: Verapamil is a widely prescribed calcium channel blocker used for the treat- 
ment of angina, hypertension and supraventricular arrhythmras. Recently, safety ques- 
tions have been raised about the concomitant utilization of verapamil with statins. 
Methods: Atowastatin is a well established statin that effectively lowers LDL cholesterol 
and triglycerides across the lo-80 mg dose range. We investigated whether there was 
any indication of an interaction between atorvastatin and verapamil as indicated by an 
increased rate of common statin-associated adverse events in the atowastatin clinical 
trial program. 
Results: To date, the program consists of 44 completed clinical trials with 9416 patients 
that have received atorvastatln. Of these 9416 patients, 292 (3.1%) have received con- 
comitant verapamil (76% on 10 mg atowastatin and 20% on 80 mg atowastatin). There 
were no incidences of myopathy, rhabdomyolysis or CPK elevations >lOxULN among 
the 292 atorvastatinlverapamil patients. The rate of treatment-emergent myalgia in 
patients taking atorvastatin/verapamil was 8/292 (2.7%). Of the patients taking atorvasta- 
tinlverapamll. 31292 (1 .O%) ware thought to have myalgia that was treatment-related. 
This rate of myalgia IS comparable to the overall rate of treatment-related myalgia seen in 
the entire 9416 patients exposed to atotvastatin in the clinical program (1.9%). Persistent 
ALT elevations >3xULN occurred in l/292 (0.3%) of the atorvastatin/verapamil patients, 
an incidence comparable to the overall rate of 0.5% seen in the entire 9416 atorvastatin 
cohort across all doses. 
Conclusion: In conclusion, data from the atowastatin clinical trial program does not cur- 
rently Indicate an increased rate of muscle or hepatic adverse events when atofvastatin 
is used concomitantly wth verapamil. Additional data will be collected with over 44000 
patients currently ongoing in clinical trials with atorvastatin. 
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1027-69 Safety and Efficacy of Nesiritide in the Treatment of 
Decompensated Heart Failure in Observation Patients 
W. Franklin Peacock, IV. Charles L. Emerman, on behalf of the PROACTION study 
group, The Cleveland Clinic Foundation, Cleveland, OH 
Background: Nesiritide (NES), B type natriuretic peptide, has been demonstrated to 
have hemodynamic and other clinical benefits for patients (pts) with decompensated 
heart failure. There has been little investigation of this agent for pts being treated in 
observation or similarly staffed units. The purpose of this study was to evaluate the 
safety, efficacy, and economic benefits of NES therapy in the less monitored sening of 
the Emergency Department (ED). 
Methods Multicenter, randomized, double blinded, pilot study of pts with decompen- 
sated heart failure evidenced by dyspnea at rest or on walking less than 20 feet. Pts were 
identified and randomized within 3 hours of ED arrival. Initial treatment was begun with 
diuretics, O,, and, if desired, morphine or non-parenteral nitrates. ACE Inhibitors were 
withheld for 3 hours. Other vasodilators and inotropes. discouraged for the first 12 hrs, 
could be used after 3 hrs. Pts received NES or placebo for at least 12 hours. Pts were 
either admitted or discharged after a maximum of 24 hours in the ED but could be contin- 
ued on study drug in the hospital. 
Results 250 pts were randomized; 237 received study drug. 56% male, mean age 65.6 
years; 47% Caucasian and 46% African-American. 61% NYHA Class III/IV at baseline 
and average EF 35%. 33 % had preserved systolic function. Mean baseline BNP level 
was 747 pg/ml. AdmissIon rate for NES was 49% vs. 55% for placebo. Admission rate for 
CHF was lower for NES (30%) than placebo (38%). Of hospitalized pts, 10% NES and 
23% placebo were rehospitalized within 30 days (p=.O58). The total LOS over 30 days, 
including the inltlal visit for pts hospitalized and then rehospitalized. was 5.5 days for 
NES vs. 10.2 days for placebo (pc.052). There was no significant difference in drug ter- 
mination, symptomatic hypotension, ventricular arrhythmias, or death between the two 
groups. The overall cost of care was lower in the NES group. drwn by decreased LOS 
and lower readmission rates over the 30 day study pertod, which neutralwed the cost of 
drug. 
Conclusions: NES is safe and effective in the treatment of emergency department/ 
observation pts. The cost of adding NES is balanced by decreased costs associated with 
admission and readmission. 
1027-90 The Resuscitative Value of B-Type Natriuretic Peptide in 
Patients With Out-of-Hospital Cardiac Arrest Due to 
Cardiac Causes 
Ken Naqaq Nariyuki Hayashi, Takeo Mukouyama, lkuyoshi Watanabe, Sumito Oguchi. 
Satoru Kikuchi. Shioemasa Tani. Kazuhiro Watanabe. Kivoshi lida. Takeo Anazawa. 
Takashi Miyamoto,?adamasa Nosaka. Katsuo Kanmatsise, Nihon University School of 
Medicine, Tokyo, Japan 
Background: B-type natrluretic peptide (BNP) is released by the ventricular myocardlum 
in response to increased wall tension. Although the circulating level of this neurohormone 
has been shown to have a prognostic value in either congestive heart failure or acute 
coronary syndromes, no data are available for a resuscitative value in out-of-hospital car- 
diac arrest. 
Methods: We conducted a prospective study of 401 patients whose BNP was measured 
on arrival at the emergency room after out-of-hospital cardiac arrest due to cardiac 
causes. The primary end point was survival to hospital discharge. 
Results: A total of 52 of the 401 patients survived to discharge from the hospital and the 
BNP level was lower among such patients than among those who died (mean+/-SD, 74+1 
-128 vs. 260+/-292pg/ml, p<O.OOl). The BNP levels ranged from 2 to 2620pg/ml. with a 
mean+/-SD of 236+/-283pg/ml, a median of 152pg/ml, and 25th and 75th percentile val- 
ues of 34 and 392pg/ml, respectively. The unadjusted rate of the SuNival decreased in a 
stepwise fashion among patients in increasing quartiles of BNP levels with quartile 1 at 
34% vs. quartile 2 at 10% vs. quartile 3 at 7% vs. quartile 4 at 1% (p<O.OOi). This associ- 
ation remained significant in subgroups of patients with witnessed arrest, bystander car- 
diopulmonary resuscitation and ventncular fibrillation in initial cardiac rhythm (pcO.001, 
respectively). After adjustment for independent predictors of resuscitation, the odds 
ratios for the suwival in the second, third and fourth quartiles of BNP were 0.14 (95% Cl, 
0.04 to 0.45). 0.10 (95% Cl, 0.03 to 0.36). and 0.008 (95% Cl, 0.0 to 0.17). A value of 
lOOpg/ml or less for BNP was the significant independent predictor of the survival with an 
adjusted odds ratio of 10.9. 
Conclusions: The measurement of BNP on arrival at the emergency room provides pre- 
dictive information for survival to hospital discharge in patients wth out-of-hospital car- 
diac arrest due to cardiac causes. 
